Regenerative Therapies Library
Every article, presentation, spotlight, and news item we've tagged to Regenerative Therapies.
Showing 97–120 of 297
Placental Cell Therapy Expands Regenerative Access in Florida
Celularity and Fountain Life are offering placental-derived cell therapy (Cenplacel-L) for investigational use in Florida under a state statute permitting physician-directed access to non-FDA-approved cell therapies. The therapy targets inflammation and age-related degeneration, positioning allogeneic cell treatment as an emerging tool in preventive longevity medicine.
Rokit accelerates trials of AI cartilage regeneration platform
Rokit Healthcare is advancing an AI-driven 3D bioprinting platform that regenerates hyaline cartilage using patients' own adipose tissue, printed in real time during surgery. A 13-institution clinical trial with over 100 patients evaluates whether this autologous approach produces more durable cartilage repair than standard procedures while eliminating the need for external cell culture and multiple surgeries.
Sustained exercise gains from bone marrow cell therapy in advanced ischemic heart disease
BioCardia's autologous bone marrow cell therapy demonstrated sustained improvements in exercise capacity and angina reduction over two years in patients with chronic myocardial ischemia who had exhausted standard interventions. The therapy showed no treatment-emergent major adverse cardiac events, with exercise tolerance gains of 179 seconds persisting through follow-up and angina episodes declining 82% at six months.
GPR40 Activation Reverses Thymic Aging
GPR40 activation via GW9508 restores thymic epithelial cell function in aged mice by suppressing senescence pathways and restoring T-cell production. This addresses immunosenescence—a primary driver of age-related vulnerability to infection, malignancy, and autoimmune dysfunction.
GPR81 activation reverses age-linked muscle lipid accumulation
Loss of the lactate receptor GPR81 drives lipid accumulation and accelerates aging hallmarks in muscle tissue. Activating GPR81 reverses these changes in both cultured cells and progeroid mice, restoring lipid oxidation capacity and muscle regeneration.
The first personalized brain repair for Parkinson’s
Aspen Neuroscience's autologous cell therapy for Parkinson's disease demonstrates early restoration of motor function and quality of life through transplantation of patient-derived dopamine-producing neurons into the brain. This represents a shift from symptomatic management toward biological reconstruction of damaged neural tissue.
Restoring the Strength of Natural Killer Cells
Natural killer cells from older adults show reduced capacity to eliminate senescent and cancer cells due to impaired granule release and cytotoxic machinery, not recognition defects. Targeting elevated Cdc42 protein and restoring microtubular organization represents a potential intervention to restore NK cell function with age.
Direct-to-Brain Stem Cells Reduce Tau in Alzheimer's
Regeneration Biomedical's direct-to-brain stem cell therapy received FDA Fast Track designation for Alzheimer's disease, following Phase 1 data showing safety, reductions in phosphorylated tau, and improved amyloid PET measures. This represents a shift toward regenerative approaches that address neurodegeneration at the cellular level rather than symptomatic management alone.
Adipose‐Specific GHR Deletion Attenuates Brain Aging and Cognitive Decline in Aged Mice
Blocking growth hormone signaling specifically in adipose tissue reduces neuroinflammation, preserves synaptic integrity, and improves cognitive performance across multiple domains in aged mice. This identifies peripheral adipose tissue as an unexpected regulator of brain aging, suggesting a therapeutic target for age-related cognitive decline.
Dopamine neuron replacement for Parkinson's gains FDA regulatory acceleration
The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Aspen Neuroscience's sasineprocel, a personalized cell therapy that replaces dopamine-producing neurons lost to Parkinson's disease rather than masking symptoms with dopamine replacement. This regulatory milestone accelerates development pathways for a therapy addressing a core mechanism of neurodegeneration—cellular loss—rather than compensating for it.
Senescence‐Driven Remodeling Defines an Aggressive and Immunomodulatory Subtype of Endometriosis
Cellular senescence in ectopic endometrial tissue drives aggressive endometriosis through a PAK4/AKT signaling loop that promotes macrophage-mediated immune remodeling. Stigmasterol, a plant-derived phytosterol, suppresses this pathway and reduces lesion invasiveness in preclinical models, suggesting a mechanism-based therapeutic approach to a senescence-driven disease subtype.
Chemotherapy Senescence Fuels Metastasis via Fructose Metabolic Reprogramming
Chemotherapy induces senescence in ovarian cancer cells, triggering release of fructose into the cellular environment that reprograms neighboring cancer cells to enhance detachment and metastatic spread. This metabolic coupling mechanism reveals a critical side effect of cancer treatment that can paradoxically promote disease progression through altered membrane cholesterol and energy metabolism.
What animals can teach us about reversing age-related disease
Researchers studying animals that recover from extreme stress—hibernating ground squirrels and aging dogs—are identifying reversible mechanisms of age-related disease that human datasets alone may never reveal. This approach reframes aging as a problem with existing biological solutions rather than inevitable decline.
Mesoblast expands into CAR platform acquisition
Mesoblast acquired exclusive worldwide rights to a chimeric antigen receptor technology platform developed at Mayo Clinic to enhance its mesenchymal stromal cell therapeutic products. This expansion targets inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, lupus nephritis, and B-cell autoimmune conditions.
AI-Designed Oral Peptides Transform Drug Delivery Science
LG AI Research and D&D Pharmatech are collaborating to use artificial intelligence for designing oral peptide therapeutics, combining AI-driven molecular discovery with proprietary formulation technology to improve bioavailability and reduce development timelines. This partnership addresses a critical gap in drug delivery: the difficulty of administering peptides orally, which could expand treatment options for diseases currently managed only through injection.
Senescent Immune Cells Drive Tumor Invasion via Glutamine-IL-1β Axis
Oxidative stress triggers metabolic reprogramming in immune cells, causing them to secrete inflammatory factors that promote squamous cell carcinoma invasion. Blocking the IL-1β signaling pathway suppresses this invasion more effectively than targeting glutamine metabolism alone, suggesting a direct therapeutic intervention point.
Telomir-Zn reactivates tumor suppressors with 50-fold selectivity
Telomir-Zn, a compound that modulates intracellular iron and copper to inhibit histone demethylases, suppressed tumor growth in preclinical prostate and triple-negative breast cancer models while maintaining a 50-fold selectivity window favoring normal cell survival. The mechanism reactivated silenced tumor-suppressor genes and showed synergistic effects with standard chemotherapy in select cancer lines, supporting advancement to clinical trials.
Intestinal Exosomes Restore Age-Related Fat Loss via miRNA Signaling
Intestinal epithelial exosomes from young mice reverse age-related subcutaneous fat atrophy in older animals by delivering a microRNA that activates lipid storage in fat progenitor cells. This gut-to-fat signaling pathway suggests a direct mechanism by which intestinal function influences systemic metabolic health during aging.
Stem cell therapy restores dopamine production in Parkinson's disease
UniXell Biotechnology obtained FDA clearance for UX-DA003, a stem cell-derived dopaminergic progenitor therapy for Parkinson's disease, following prior approval in China. Preclinical data demonstrate 50-60% functional dopaminergic neuron purity with reduced clinical dosing requirements, positioning this as a potential regenerative intervention in a neurodegenerative condition where current pharmacological approaches have limited disease-modifying capacity.
Selective protein degradation targets aggregates in neurodegeneration
TrimTech Therapeutics secured $14 million in additional seed funding to advance protein degradation platforms targeting neurodegenerative disease. The company's approach selectively removes toxic protein aggregates while preserving functional proteins, addressing a mechanistic gap in current neurodegeneration therapies.
Thbs1 Blocks Bone Repair Through Immune Cell Mitochondrial Damage
Senescent bone marrow cells release thrombospondin-1 (Thbs1), which impairs mitochondrial cleanup in immune cells, driving chronic inflammation and blocking bone formation in aging. Blocking this protein restored bone repair in aged animals, identifying a specific therapeutic lever for age-related bone decline.
FDA Panel Approves Peptides Its Scientists Rejected
An FDA advisory panel voted to recommend six of seven experimental peptides for pharmacy compounding despite the agency's own scientific review recommending against all of them. The decision relocates supply chains from gray-market importers to regulated pharmacies but does not constitute validation of efficacy or safety.
Aspen’s autologous cell therapy shows promising Phase 1/2a results
Aspen's autologous iPSC-derived dopaminergic cell therapy demonstrated clinically meaningful improvements in motor function and quality of life in early Parkinson's disease patients, with durable cell engraftment and acceptable safety profile at 12 months. This represents a regenerative medicine approach that bypasses the need for immunosuppression by using a patient's own reprogrammed cells.
A one-shot cure for diabetes? Sana Biotechnology makes its move
Sana Biotechnology and Mayo Clinic are advancing SC451, a cell therapy that replaces destroyed pancreatic islet cells in Type 1 diabetes by engineering them to evade immune attack, potentially eliminating the need for lifelong insulin management. Early data shows transplanted cells remaining functional for over a year without immunosuppression, establishing a proof-of-concept for broader tissue replacement applications.